Proparacaine
Local Anesthetic — SENSORY ORGANS
Also known as: ophthaine, proparacaine HCl, proparacaine hydrochloride, proxymetacaine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Proparacaine is an ofp drug in the Local Anesthetic class catalogued in DrugCentral. It was first approved by the FDA in 1953. DrugCentral lists 4 molecular targets, including SIGMAR1, MAOA and SCN1A|SCN2A|SCN3A. Recorded indications include Administration of Corneal Anesthesia and Local Anesthesia for Ophthalmologic Procedure.
- Approval status: ofp (first approved 1953 by the FDA).
- Drug class: Local Anesthetic.
- Molecular targets: SIGMAR1, MAOA, SCN1A|SCN2A|SCN3A and SCN10A (4 listed in DrugCentral).
- Indications: Administration of Corneal Anesthesia and Local Anesthesia for Ophthalmologic Procedure.
- ATC code: S01HA04 (Local anesthetics).
- Molecular formula: C16H26N2O3; molecular weight 294.39 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Administration of Corneal Anesthesia
- Local Anesthesia for Ophthalmologic Procedure
Contraindications (4)
- Eye infection
- Heart disease
- Hyperthyroidism
- Uveitis
Mechanism & targets
| Established pharmacologic class | Local Anesthetic |
|---|
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sigma non-opioid intracellular receptor 1 | SIGMAR1 | unknown | Ki 7.00 |
| Amine oxidase [flavin-containing] A | MAOA | unknown | IC50 5.75 |
| Sodium channel alpha subunits; brain (Types I, II, III) | SCN1A|SCN2A|SCN3A | blocker | IC50 5.72 |
| Sodium channel protein type 10 subunit alpha | SCN10A | blocker | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1953-07-01 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
S01HA04 | SENSORY ORGANS › OPHTHALMOLOGICALS › LOCAL ANESTHETICS › Local anesthetics |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Conjunctival hyperaemia | 359.5 |
| Hypopyon | 337.3 |
| Corneal oedema | 319.8 |
| Corneal epithelium defect | 304.8 |
| Endophthalmitis | 220.8 |
| Retinopathy of prematurity | 216.9 |
| Keratopathy | 213.9 |
| Corneal infiltrates | 211.1 |
| Persistent corneal epithelial defect | 208.0 |
| Ulcerative keratitis | 202.4 |
| Eye pain | 188.6 |
| Visual acuity reduced | 177.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Proparacaine is on its molecule page.
| Molecular formula | C16H26N2O3 |
|---|---|
| Molecular weight | 294.39 g/mol |
| CAS number | 499-67-2 |
| InChIKey | KCLANYCVBBTKTO-UHFFFAOYSA-N |
| PubChem CID | 4935 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Proparacaine used for?
DrugCentral lists the following indications for Proparacaine: Administration of Corneal Anesthesia and Local Anesthesia for Ophthalmologic Procedure.
How does Proparacaine work?
Its molecular targets in DrugCentral include SIGMAR1, MAOA, SCN1A|SCN2A|SCN3A (blocker) and SCN10A (blocker).
When was Proparacaine first approved?
Proparacaine was first approved by the FDA in 1953.
What drug class does Proparacaine belong to?
Proparacaine is in the Local Anesthetic class.
What is the chemical formula of Proparacaine?
Proparacaine has the molecular formula C16H26N2O3 and a molecular weight of 294.39 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2294 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1196 — compound record and bioactivity
- PubChem CID 4935 — chemical identifiers
- DrugBank DB00807 — drug record
- FDA UNII B4OB0JHI1X — substance identity
- DailyMed: FDA labels for Proparacaine — current prescribing information (label search)
- UniProt Q99720 (SIGMAR1) — target protein
- UniProt P21397 (MAOA) — target protein
- UniProt Q9Y5Y9 (SCN10A) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.